Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cosmic: Setrusumab vs Bisphosphonates in Pediatric Osteogenesis Imperfecta
NCT05768854Phase 3Active, not recruiting
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Jun 2023
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, open-label trial of setrusumab in osteogenesis imperfecta (OI) (2 arms), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoint: Annualized Rate of All Radiographically-Confirmed Fractures, Including Morphometric Vertebral Fractures at 24 months. Started Jun 2023; status: active, not recruiting.
02
Drugs
setrusumab
03
Conditions
osteogenesis imperfecta (OI)
Beyond the preview
Go deeper on NCT05768854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05768854.